Therapeutic options for the highly pathogenic human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the current pandemic coronavirus disease (COVID-19) are urgently needed.
COVID-19 is associated with
viral pneumonia and
acute respiratory distress syndrome causing significant morbidity and mortality. The proposed treatments for
COVID-19 have shown little or no effect in the clinic so far. Additionally, bacterial and fungal pathogens contribute to the SARS-CoV-2-mediated
pneumonia disease complex. The antibiotic resistance in
pneumonia treatment is increasing at an alarming rate. Therefore,
carbon-based nanomaterials (CBNs), such as
fullerene,
carbon dots,
graphene, and their derivatives constitute a promising alternative due to their wide-spectrum antimicrobial activity, biocompatibility, biodegradability, and capacity to induce tissue regeneration. Furthermore, the antimicrobial mode of action is mainly physical (e.g., membrane distortion), characterized by a low risk of antimicrobial resistance. In this Review, we evaluated the literature on the
antiviral activity and broad-spectrum antimicrobial properties of CBNs. CBNs had
antiviral activity against 13 enveloped positive-sense single-stranded RNA viruses, including SARS-CoV-2. CBNs with low or no toxicity to humans are promising
therapeutics against the
COVID-19 pneumonia complex with other viruses, bacteria, and fungi, including those that are multidrug-resistant.